CIZUMAB 100MG INJ

Product Description

• Active Ingredient: Bevacizumab (100mg per 4ml vial).
• Mechanism of Action: It is a recombinant humanized monoclonal antibody (a type of targeted therapy) that works as an anti-angiogenic agent. It selectively binds to a protein called vascular endothelial growth factor A (VEGF-A), which plays a key role in the formation of new blood vessels that supply oxygen and nutrients to tumors. By blocking VEGF-A, Cizumab effectively cuts off the tumor's blood supply, which slows down the cancer's growth and spread (metastasis).
• Administration: It is administered by a doctor or nurse as an intravenous (IV) infusion in a clinical setting. It should not be self-administered. The initial infusion typically lasts for 90 minutes and may be reduced to 30 minutes in subsequent sessions if well-tolerated.
• Storage: The medication is a solution for infusion and must be stored in a refrigerator between 2C to 8C. It should not be frozen or shaken. 

• Metastatic colorectal cancer
• Non-small cell lung cancer (non-squamous)
• Advanced kidney cancer (renal cell carcinoma)
• Brain tumor (glioblastoma multiforme)
• Ovarian, fallopian tube, or primary peritoneal cancer
• Metastatic cervical cancer
• Hepatocellular carcinoma (liver cancer) in some cases